
Komal Jhaveri, MD, FACP
Medical Oncologist
Titles
Section Head, Endocrine Therapy Research Program; Clinical Director, Early Drug Development Service
Clinical Expertise
Breast Cancer; Early-Phase Clinical Trials
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
- 646-888-4226 Early Drug Development; Mon-Fri, 9AM-5PM ET
- 833-305-1338 Breast Medicine; Mon-Fri, 8AM-6PM ET
Dr. Jhaveri accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 646-888-5157 Office Phone
- Speaks English and Hindi

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, University of Mumbai
Residencies
Nuclear Medicine - Radiation Medicine Center/Tata Memorial Hospital; Internal Medicine - St. Luke's-Roosevelt Hospital Center/Columbia University
Fellowships
Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine; Medical Oncology
I am a medical oncologist dedicated to caring for people with breast cancer. Each year, I provide care to approximately 300 people across Memorial Sloan Kettering Cancer Center (MSK) in Manhattan and the David H. Koch Center for Cancer Care. I am fortunate to have a career that I’m passionate about and that allows me to help so many people, both in the clinic and through research that may impact cancer care in the future.
Read more
When patients first meet with me, I take time to address their concerns about their diagnosis and answer their questions regarding treatment and prognosis. I try to lessen their anxiety and earn their trust so they feel comfortable in my presence. It is important to me that patients know they are in good hands with me, and with their experienced clinical care team, which includes a registered nurse, a nurse practitioner, or a physician assistant. When needed, I also refer patients to a social worker, a support group, and/or integrative medicine services. These resources can help patients cope and improve their overall wellbeing.
Some people may wonder if they did something wrong or are somehow responsible for developing cancer, but I reassure them that it is not their fault. Whether a person has early-stage disease or their cancer has metastasized (spread), I help them focus on what we can do and encourage them with information about research developments and new treatment options that may benefit them. We talk about exciting advances in the field that have led to our ability to cure patients, achieve long-term remissions, and prolong survival while maintaining quality of life, even for those with late-stage disease. In instances when patients are not able to receive treatment or do not wish to pursue therapy, I help them navigate those decisions.
Medical oncology is a unique subspecialty because it allows doctors and patients to cultivate close relationships and, in most cases, requires continuity of care. I chose this field not only because I wanted to understand the science and biology behind what drives cancer while working to find a cure or ways to improve patient outcomes, but also to develop long-term relationships with patients and their families. Patients let me into the most intimate aspects of their lives; I am privileged to be able to celebrate their happy moments and, in other instances, to guide them and their loved ones through very difficult times.
At MSK, I conduct translational research in collaboration with my laboratory colleagues to shepherd our findings from the lab to the clinic. Through my research, I aim to accelerate the development of new treatments and improve outcomes for people with breast cancer. Our latest work involves the use of acquired biospecimen (cell-free DNA and tumor) analyses and imaging studies to identify and understand biomarkers indicating response or resistance to breast cancer treatment.
As the section head for the Endocrine Therapy Research Program, I manage the clinical trial portfolio for hormone receptor-positive HER2-negative/low breast cancer. I am currently involved with trials evaluating novel PI3K inhibitors, new endocrine drugs used alone or in combination with other drugs, and antibody drug conjugates, among other investigational therapies. I also serve as the Clinical Director for the Early Drug Development Service. This work positions me as the principal investigator for many exciting phase 1 trials led by this service.
Outside of work, I enjoy traveling and playing board games with my family. I also like to relax by participating in my book club and stay active by skiing, dancing, and playing tennis.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Jhaveri
- A Phase I Study of ZW49 in Inoperable or Metastatic HER2-Positive Cancers
- Clinical Trials Co-Investigated by Dr. Jhaveri
- A Phase I Study of BDC-1001 Alone or in Combination with Pembrolizumab Immunotherapy in People with Advanced Solid Tumors that Make Too Much HER2
- A Phase I Study of BDC-1001 Alone or in Combination with Pembrolizumab Immunotherapy in People with Advanced Solid Tumors that Make Too Much HER2
- A Phase I Study of DS-1062a in People with Advanced Digestive Cancers
Read more
- A Phase I Study of RLY-2608 Alone in People with Solid Tumors or in Combination with Fulvestrant in People with Breast Cancer
- A Phase I Study of RMC-5552 in People with Persistent Solid Tumors
- A Phase I Study of RP-6306 to Treat Advanced Solid Tumors with Certain Genetic Changes
- A Phase I/II Study of [225Ac]-FPI-1434 in People with Advanced or Metastatic Solid Tumors
- Preventing High Blood Sugar with Ketogenic or Low Carbohydrate Diets or Medication in People Being Treated for Metastatic Breast Cancer

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Jhaveri K, Juric D, Yap Y, Cresta S, Layman R, Duhoux F, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A phase 1 study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib in patients with estrogen receptor-positive breast cancer. Clin Cancer Res. 2021;27(21):5760-70. PMID: 34433648
Jhaveri K, Drago J, Shah P, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier M, Sklarin N, Chandarlapaty S, and Modi S A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer. Clin Cancer Res. 2021;27(14):3867-3875. PMID: 33947692
Jhaveri K, dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg J, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy M, Modi S. Measuring tumor epichaperome expression using [124I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer. JCO Precision Oncology. 2020;4:PO.20.00273. PMCID: PMC7713524
Jhaveri K*, Wang XV, Makker V, Luoh S-W, Mitchell E-P, Zwiebel J-A, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) inpatients with HER2-amplifiedtumors excluding breast and gastric/gastroesophageal junction(GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann of Oncol. 2019;30(11):1821–30. PMCID: PMC6927318
Jhaveri K, Chang M , Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2020 Nov 4; clincanres.2657.2020
Visit PubMed for a full listing of Dr. Jhaveri’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Komal Jhaveri discloses the following relationships and financial interests:
-
AstraZeneca
Provision of Services -
Blueprint Medicines
Provision of Services -
Genzyme
Provision of Services -
Intellisphere, LLC
Provision of Services -
Loxo Oncology
Provision of Services -
Medscape
Provision of Services -
Novartis Pharmaceuticals Corporation
Provision of Services
-
OncLive
Provision of Services -
Pfizer, Inc.
Provision of Services -
Physicians' Education Resource
Provision of Services -
Plexus Communications
Provision of Services -
Rain Therapeutics Inc.
Provision of Services -
Roche
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].